Physician

Eric Seifter, M.D.

According to 2025 Medicare claims, Eric Seifter, M.D. (NPI: 1376544841) practices medical oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Baltimore, MD. This provider's primary affiliated billing organization is GREENSPRING PERSONAL ONCOLOGY LLC (NPI: 1598470551) and primary practice location at 21093-4685.

Seifter's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 507 traditional Medicare patients, billed 164,349 HCPCS/CPT codes, and received $3,326,748 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,156 prescription claims across 200 beneficiaries totaling $5,625,736 in drug costs, led by Pomalyst (Pomalidomide). 2023 DME data shows 47 claims. Open Payments data shows 6 records totaling $103. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,152,838 and ending at $3,326,748. Concurrently, Part D prescription costs have risen steadily, from $577,724 to $5,625,736. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,434 and ending at $2,456.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	377	135,953	$2,152,838
2016	386	152,459	$2,816,095
2017	400	172,692	$3,379,638
2018	406	176,869	$3,283,501
2019	415	164,074	$3,087,754
2020	444	171,769	$3,830,776
2021	491	141,060	$2,798,392
2022	502	157,792	$2,596,613
2023	488	178,158	$2,598,245
2024	507	164,349	$3,326,748

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	2,161	$577,724
2016	187	2,024	$590,686
2017	194	2,368	$1,673,616
2018	199	2,307	$1,857,737
2019	208	2,502	$2,785,578
2020	213	2,548	$3,357,148
2021	230	2,451	$3,984,130
2022	232	2,169	$3,608,108
2023	199	2,055	$4,235,587
2024	200	2,156	$5,625,736

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$1,188
2016	N/R	22	$993
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	47	$2,404
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	166	346	$137
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	145	314	$94
J0897	Injection, denosumab, 1 mg	151	20,220	$20
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	149	289	$13
96372	Injection of drug or substance under skin or into muscle	166	533	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	40	1,134	$919,050
Brukinsa	Zanubrutinib	48	1,426	$687,585
Calquence	Acalabrutinib Maleate	48	1,440	$667,892
Imbruvica	Ibrutinib	31	984	$552,477
Lenalidomide	Lenalidomide	39	1,092	$484,736

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$103	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eric Seifter, M.D.?

Tedicare shows public-source Medicare data for Eric Seifter, M.D. (NPI 1376544841), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eric Seifter, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eric Seifter, M.D.?

Eric Seifter, M.D. is linked to GREENSPRING PERSONAL ONCOLOGY LLC (billing NPI 1598470551) in the available physician profile data.

Does Eric Seifter, M.D. have Open Payments data?

Eric Seifter, M.D. has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.